• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 363
  • 187
  • 134
  • 25
  • 25
  • 25
  • 25
  • 25
  • 25
  • 8
  • 7
  • 3
  • 3
  • 2
  • 2
  • Tagged with
  • 605
  • 605
  • 196
  • 194
  • 165
  • 107
  • 98
  • 93
  • 76
  • 66
  • 63
  • 57
  • 54
  • 54
  • 48
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
381

Neuropatia periférica induzida por quimioterapia e sua associação com quedas e síndrome das pernas inquietas / Peripheral neuropathy induced by chemotherapy and its association with falls and restless legs syndrome

Ferreira, Lis Campos 24 August 2018 (has links)
Introduction: Chemotherapy-induced peripheral neuropathy (CIPN) is a common and often dose-limiting side effect. Restless Legs Syndrome (RLS) is also a common sensory-motor neurological disorder, characterized by uncomfortable and unpleasant sensations in the legs, followed by an urgency to move them. The presence of CIPN has been associated with the risk of falls in cancer survivors. Objectives: To determine the frequency and factors associated with falls in chemotherapy patients, and to evaluate the possible association between suggestive symptoms of CIPN, RLS and falls. Design: A total of 234 oncological patients undergoing chemotherapy treatment were interviewed, with questions regarding sociodemographic data, diagnosis, treatment and occurrence of falls. Besides, it was used the Chemotherapy Induced Peripheral Neuropathy Assessment Tool (CIPNAT) and diagnostic criteria for SPI. Results: The mean age of the sample was 53.4 years (± 13.1), of which 73.9% were female. Suggestive symptoms of CIPN were present in 51.7% of the patients, and falls were reported in 30.7%. There was association between the presence of neuropathic symptoms and falls (p = 0.0191), with a 1.65 fold increase in the prevalence of falls compared to patients without neuropathic symptoms. In individuals younger than 65 years of age, we observed a greater association between CIPN symptoms and falls (p = 0.0016). Patients with falls had a higher score on items that assessed interference in daily life activities. In addition, there was also a statistically significant association of RLS with symptoms of CIPN (p = 0.0005), RLS with falls (p = 0.0152), and RLS associated with neuropathic symptoms with falls (p = 0.0061). Conclusions: The findings of the present study suggest that falls are common in chemotherapy patients, and symptoms of CIPN and RLS contribute to increased falls. Moreover, these two disorders, when associated, act synergistically, further increasing the prevalence of falls. / Introdução: A neuropatia periférica induzida por quimioterapia (NPIQ) é um efeito colateral comum e frequentemente dose-limitante. A Síndrome das Pernas Inquietas (SPI) também é uma desordem neurológica sensitivomotora comum, caracterizada por sensações desconfortáveis e desagradáveis nas pernas, seguidas de urgência em movimentá-las. A presença de NPQI tem sido associada ao risco de quedas em sobreviventes de câncer. Objetivos: Determinar a frequência e os fatores associados a quedas em pacientes em quimioterapia, e avaliar possível associação entre sintomas sugestivos de NPIQ, SPI e quedas. Métodos: Foram entrevistados 234 pacientes oncológicos em tratamento quimioterápico, com perguntas referentes a dados sociodemográficos, diagnóstico, tratamento e ocorrência de quedas, além de ter sido utilizada a Ferramenta de Avaliação de Neuropatia Periférica Induzida por Quimioterapia (FANPIQ) e aplicados critérios diagnósticos para SPI. Resultados: A média de idade da amostra foi de 53.4 anos (±13.1), sendo 73.9% do sexo feminino. Sintomas sugestivos de NPIQ estavam presentes em 51.7% dos pacientes, e em 30.7% foram relatadas quedas. Houve associação entre a presença de sintomas neuropáticos e quedas (p = 0.0191), com aumento de 1.65 vezes na prevalência de quedas em relação aos pacientes sem sintomas neuropáticos. Em indivíduos com menos de 65 anos observamos uma maior relação entre sintomas de NPIQ e quedas (p=0.0016). Pacientes com quedas apresentaram uma pontuação maior nos itens que avaliam a interferência nas atividades de vida diária. Além disso, também houve associação estatisticamente significante de SPI com sintomas de NPIQ (p=0.0005), SPI com quedas (p=0.0152), e SPI associada a sintomas neuropáticos com quedas (p=0.0061). Conclusões: Os achados do presente estudo sugerem que quedas são frequentes nos pacientes em quimioterapia, e sintomas de NPIQ e SPI contribuem para o aumento de quedas. E mais, que estas duas desordens, quando associadas, agem de forma sinérgica, aumentando ainda mais a prevalência de quedas. / Aracaju
382

Capacidade funcional e qualidade de vida de mulheres com câncer de mama após o tratamento oncológico / Functional Capacity and Quality of Life in women with breast cancer after breast cancer treatment

Leticia Meda Vendrusculo 25 May 2011 (has links)
Estudo descritivo, quantitativo que teve como objetivo comparar a Capacidade Funcional de mulheres com câncer de mama, que realizaram tratamento oncológico (G1), com a de mulheres que nunca apresentaram diagnóstico de câncer (G2), e identificar se a qualidade de vida de mulheres com neoplasia mamária correlaciona-se com a capacidade funcional. O G1 foi composto por 42 mulheres submetidas ao tratamento para o câncer de mama, até um ano do período da coleta de dados, e que frequentavam um núcleo de reabilitação. O G2 foi composto por 42 mulheres, pareadas com o G1, por idade e nível sócio-econômico. A coleta de dados se deu no período de janeiro a julho de 2009. Os instrumentos utilizados para a comparação da Capacidade Funcional foram Índice de Katz e Índice de Lawton, e para a Qualidade de Vida, o EORTC QLQ-C30 e EORCT QLQ-BR23. Os resultados mostraram que o G1 apresentou leve comprometimento nas condições físicas, como fadiga, imagem corporal, função sexual, função física e sintomas na mama e no braço, e moderadas alterações psicossociais na função emocional e nas atividades de lazer e de participação social, comprometendo, assim, sua QV. A comparação entre G1 e G2 mostrou que o tratamento oncológico prejudicou muito a realização das AIVDs das integrantes do G1, porém não interferiu nas ABVD. Acredita-se que os resultados referentes às ABVDs se devam ao fato de elas frequentarem um núcleo de reabilitação e receberem orientações para continuar realizando as ABVDs, mesmo no período pós-operatório. Além disso, participar do núcleo pode ter contribuído para a manutenção do autocuidado e ser também uma importante estratégia para o melhor enfrentamento das limitações físicas e emocionais impostas pelo câncer de mama. O período de realização da coleta dos dados, ao término dos tratamentos, também pode ter favorecido a indicação, pelas componentes do G1, de um menor comprometimento de alguns eventos adversos ao tratamento e alterações psicossociais. No entanto, evidenciou-se ainda, com os resultados relativos às AIVDs, a importância de um maior investimento no cuidado à mulher com câncer de mama, em relação à sua QV e CF, no que se refere às funções física, emocional e social. Sugere-se a realização de estudos de abordagem qualitativa que façam uma avaliação subjetiva dos comprometimentos dos eventos adversos dos tratamentos, das alterações psicossociais para as mulheres com câncer de mama e das estratégias de que elas se utilizam para vivenciá-los. Outras investigações poderão abordar ainda aspectos individuais no DO, como as AIVDs e atividades de lazer; avaliar a eficácia de serviços de reabilitação no manejo dos sintomas, como dor, fadiga, insônia, perda de apetite, aderência cicatricial e outros, além do papel frente às alterações psicossociais; e avaliar as demais categorias que integram o DO de mulheres com câncer de mama, para compreender a influência desta doença sobre aspectos como os de repouso e sono, educação, trabalho e participação social, a fim de possibilitar uma melhor intervenção multidisciplinar junto a esta população. / This descriptive study aimed to compare the functional capacity of women with breast cancer who underwent treatment (G1), with women who never had cancer (G2), and identify if the quality of life of women with breast cancer correlates with functional capacity.G1 was composed of 42 women undergoing treatment for breast cancer, up to a year of data collection, and who attended a rehabilitation center. The G2 is the G1 paired by age and socioeconomic status. Data collection took place from January to July 2009. The instruments used for comparison were the Functional Capacity Index Katz and Lawton Index, and Quality of Life, EORTC QLQ-C30 and QLQ-BR23 EORCT. The results showed that G1 showed mild impairments in physical conditions such as fatigue, body image, sexual function, physical function and symptoms in breast and arm, and moderate changes in the psychosocial and emotional function in leisure activities and social participation, compromising thus their QOL. The comparison between G1 and G2 showed that cancer treatment was very damaging to the performance of IADL members of G1, but did not interfere with ABVD. It is believed that the results concerning the ABVD be attributed to the fact that they attend a rehabilitation unit and received guidance to continue performing the ADL, even in the postoperative period. Moreover, the core part may have contributed to the maintenance of self-care. Thus, attending a rehabilitation service can be an important strategy to better cope with the emotional and physical limitations imposed by breast cancer. The timing of data collection at the end of treatments, may also have favored the statement, the components of the G1, a lower commitment of some adverse events related to treatment and psychosocial changes. However, there was still, with the results for the AIVD, the importance of increased investment in care for women with breast cancer in relation to their QOL and CF, with regard to the functions physically, emotionally and socially. It is suggested for studies of a qualitative approach to make a subjective evaluation of the commitments of the adverse events of treatment, the psychosocial changes for women with breast cancer and strategies that they use to experience them. Further investigation will also address individual aspects of the DO, as the IADL and leisure activities, evaluate the effectiveness of rehabilitation services in the management of symptoms such as pain, fatigue, insomnia, appetite loss, scar tissue and others, besides the paper front psychosocial changes, and evaluate the other categories that comprise the OD of women with breast cancer, to understand the influence of this disease on aspects such as rest and sleep, education, employment and social participation, to enable a better multidisciplinary intervention with this population.
383

Avaliação do uso do laser de baixa intensidade e do ligth-emitting diode (LED) no comportamento de fibroblastos e na redução da incidência da mucosite bucal em crianças sob tratamento quimioterápico / Evaluation of the use of low-intensity laser and Light-Emitting Diode (LED) on the behavior of fibroblasts and in reducing the incidence of oral mucositis in children under chemotherapy

Luiz Evaristo Ricci Volpato 17 July 2009 (has links)
Avaliou-se o uso do laser de baixa intensidade e do Light-Emitting Diode (LED) no comportamento de fibroblastos e na redução da incidência da mucosite bucal em crianças sob tratamento quimioterápico. Para tanto, o estudo foi executado em dois períodos experimentais distintos. No primeiro período, foi realizada a análise da viabilidade de fibroblastos Balb/c 3T3 cultivados sob déficit nutricional irradiados com laser vermelho (660nm, 40mW), laser infravermelho (780nm, 50mW) e LED vermelho (637 ± 15nm, 40mW) por 4 e 8 segundos através dos ensaios de redução do MTT e captação do vermelho neutro. No segundo período experimental realizouse ensaio clínico randomizado duplo-cego para avaliar a eficácia do laser vermelho (660nm, 40mW) e do LED vermelho (637 ± 15nm, 40mW) na redução da incidência e da severidade da mucosite bucal e da dor relacionada em crianças portadoras de câncer submetidas a quimioterapia utilizando-se o sistema de graduação da mucosite bucal da Organização Mundial de Saúde e a Escala de Dor de Faces Revisada associada à escala analógica visual. A análise estatística foi realizada utilizando-se o teste não paramétrico de Kruskal-Wallis e analise de variância do modelo linear geral com nível de significância de 5% (p = 0,05). Observou-se com a redução do MTT uma tendência de aumento da proliferação celular relacionado diretamente com o tempo de irradiação, no entanto, não significante estatisticamente. Após 72 horas, os grupos que apresentaram maior proliferação celular foram: grupo irradiado com laser infravermelho, grupo irradiado com LED, grupo irradiado com laser vermelho, grupo controle positivo e grupo controle negativo. Já através da captação do vermelho neutro, após 72 horas o grupo que apresentou maior proliferação celular foi o grupo controle positivo (cultivado sob condições nutricionais ideais) seguido pelo grupo irradiado com laser infravermelho, grupo controle negativo e grupos irradiados com LED e laser vermelho. Através da análise dos resultados obtidos e considerando os parâmetros e protocolo de fototerapia utilizados, pode-se concluir que a fototerapia com laser de baixa intensidade e diodo emissor de luz (LED) não apresentaram toxicidade em nível celular, vindo mesmo a estimular a proliferação dos fibroblastos cultivados sob déficit nutricional, sobretudo no grupo irradiado com o laser infravermelho (780nm, 50mW). A incidência e a severidade da mucosite bucal, assim como a dor associada, foram muito baixas nos grupos irradiados com laser vermelho (660nm, 40mW) e LED (637 ± 15nm, 40mW). Não houve diferença estatisticamente significativa entre os grupos; A coerência da luz não interferiu no resultado da fototerapia in vitro e in vivo. / The use of low-intensity laser and Light-Emitting Diode (LED) on the behavior of fibroblasts and in reducing the incidence of oral mucositis in children under chemotherapy were evaluated. The study was performed in two separate experiments. In the first moment, the viability of fibroblasts Balb/c 3T3 cultured under nutritional stress irradiated with red laser (660nm, 40mW), infrared laser (780nm, 50mW) and red LED (637 ± 15nm, 40mW) for 4 and 8 seconds was analyzed through the MTT and neutral red assays. The second experiment carried out was a double-blind randomized clinical trial aiming to assess the effectiveness of red laser (660nm, 40mW) and red LED (637 ± 15nm, 40mW) in reducing the incidence and severity of oral mucositis and related pain in children with cancer undergoing chemotherapy using the World Health Organization oral mucositis grading system and the Faces Pain Scale - Revised associated with a visual analogue scale. Statistical analysis was performed using the Kruskal-Wallis nonparametric test and ANOVA with a significance level of 5% (p = 0.05). It was observed with the MTT assay a trend of cell proliferation increase directly related to the irradiation time, however, not statistically significant. After 72 hours, the groups that showed higher cell proliferation were: infrared laser irradiated group, LED irradiated group, red laser irradiated group, positive control group and negative control group. By the neutral red assay, though, after 72 hours the group that showed higher cell proliferation was the positive control (grown under ideal nutritional conditions) followed by the group irradiated with infrared laser, the negative control group and groups irradiated with red laser and LED. By analyzing the results and considering the used parameters and phototherapy protocol, it is plausible to conclude that phototherapy with lowintensity laser and light emitting diode (LED) showed no toxicity at cellular level, even stimulating the proliferation of fibroblasts cultured under nutritional stress, especially in the group irradiated with infrared laser (780nm, 50mW). The incidence and severity of oral mucositis and associated pain, were very low in the groups irradiated with red laser (660nm, 40mW) and LED (637 ± 15nm, 40mW). There was no statistically significant difference between these groups, the coherence of light did not affect the outcome of phototherapy in vitro and in vivo.
384

"Aspectos da personalidade associados ao tratamento do câncer do reto baixo: abordagem psicodinâmica" / Aspects of personality associated with low rectal cancer treatment : psychodynamic approach

Maria Adelaide Gallo Ferreira de Camargo 25 November 2005 (has links)
Para investigar clinicamente aspectos da personalidade de 30 pacientes provenientes do Ambulatório do Serviço de Cirurgia de Cólon, Reto e Ânus da Divisão de Clínica Cirúrgica II do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo submetidos à radioquimioterapia como primeira abordagem ao tratamento de câncer de reto distal, utilizou-se técnica psicológica de bases psicodinâmicas. Alguns doentes não foram operados, outros submetidos à intervenção cirúrgica com ou sem colostomia definitiva, sendo continuamente tratados há pelo menos três anos. Verificou-se que os três subgrupos apresentam-se em condições emocionais semelhantes embora os pacientes do gênero masculino tenham revelado melhores condições de elaboração do luto pelas perdas causadas pela doença / In order to investigate personality clinical aspects from 30 patients, proceeding from Colon, Rectum and Anus Surgery Service Ambulatory of Surgical II Clinical Division from the Medicine School Hospital of University of Sao Paulo, Brazil, submitted to radio chemotherapy as the first approach to low rectum cancer treatment, psychological technique on psychodynamic base was utilized. Some patients were not operated, others were submitted to operation requiring or not a permanent colostomy, all of them clinically assisted along three years at least. It was found the three subgroups reveal themselves in analogous emotional conditions nevertheless men probe better than women, to elaborate mournfulness for losses succeeded by the illness
385

Adesão ao tratamento na doença renal crônica

Magacho, Edson José de Carvalho 25 January 2010 (has links)
Submitted by Renata Lopes (renatasil82@gmail.com) on 2017-03-29T17:33:39Z No. of bitstreams: 1 edsonjosedecarvalhomagacho.pdf: 642099 bytes, checksum: 1b2e21e4489c6bef6338142877dc177b (MD5) / Approved for entry into archive by Adriana Oliveira (adriana.oliveira@ufjf.edu.br) on 2017-03-30T11:23:00Z (GMT) No. of bitstreams: 1 edsonjosedecarvalhomagacho.pdf: 642099 bytes, checksum: 1b2e21e4489c6bef6338142877dc177b (MD5) / Made available in DSpace on 2017-03-30T11:23:00Z (GMT). No. of bitstreams: 1 edsonjosedecarvalhomagacho.pdf: 642099 bytes, checksum: 1b2e21e4489c6bef6338142877dc177b (MD5) Previous issue date: 2010-01-25 / Trata da avaliação da adesão medicamentosa em pessoas que desenvolveram a doença renal crônica já que favorece a ocorrência de desfechos clínicos desfavoráveis. O uso irregular das medicações pode impactar desfavoravelmente o curso da doença renal crônica (DRC), relativamente à progressão da doença e ocorrência de morbimortalidade cardiovascular. O presente estudo objetivou identificar os fatores associados à adesão medicamentosa em pacientes com doenças renais, acompanhados num ambulatório de nefrologia de atendimento multidisciplinar. Trata-se de um estudo de coorte prospectivo, realizado por um ano a partir de outubro de 2007, envolvendo 149 pacientes, convidados a participar do estudo no momento do seu comparecimento para consulta. A adesão medicamentosa foi avaliada pelo método do autorrelato em entrevista no início da pesquisa (período basal) e 12 meses após. Foi avaliada a adesão às classes medicamentosas de anti-hipertensivos betabloqueadores (BB), inibidores da enzima de conversão da angiotensina (IECA), bloqueador de receptor da angiotensina (BRA), bloqueadores de canais de cálcio (BcCa), diuréticos, às estatinas e ao ácido acetil salicílico. Foi considerado aderente o paciente que relatou os medicamentos e respectivas quantidades de comprimidos em uso prescrito na consulta que antecedeu a entrevista. O teste Minimental State Examination (MMSE) foi utilizado para excluir pacientes com declínio cognitivo. Na análise univariada realizada no período basal, os pacientes aderentes (82,6%) diferiram dos não aderentes (17,4%) por apresentar menor média de idade (49 ± 16,8 vs 59 ± 14,1, p=0,006), fazer uso de menor número de comprimidos por dia (6,3 ± 3,9 vs 8,5 ± 4,3, p=0,008), apresentar menor média de creatinina sérica (1,84 ± 0,91 vs 2,32 ± 1,25, p=0,030), maior média de filtração glomerular (52,1 ± 29,31 vs 35,24 ± 19,03, p=0,01), não apresentar a doença coronariana (0R=0,295,IC95%=[0,096-0,902],p=0,037) como comorbidade mais frequente, e não depender de cuidador na administração dos seus medicamentos (0R=4,163,IC95%=[1,688-10,269],p=0,003). Após ajuste do modelo de regressão logística, permaneceram como fatores significativamente associados à não adesão o uso de mais que cinco comprimidos por dia (IC95%=[0,99-7,41],p=0,052) e a administração da medicação feita por terceiros (OR=3,53,IC95%=[1,39-8,89],p=0,007). Na avaliação longitudinal foi observado que o percentual de não aderência aumenta com o tempo, quando se compara o período basal com a avaliação final aos 12 meses (17% VS 27%, p= 0,04). Conclusão: Na população estudada, a não aderência foi identificada em 17,8% de pacientes e apresentou associação significativa com o maior número de comprimidos em uso por dia e à administração dos medicamentos por terceiros e aumenta com o passar do tempo. / Introduction: Non-adherence to drug therapy favors the occurrence of adverse clinical outcomes in chronic diseases. Irregular use of medications can adversely impact the course of chronic kidney disease (CKD), regarding disease progression and occurrence of cardiovascular morbidity and mortality. This study aimed at identifying factors associated with drug therapy in patients with kidney disease, followed in an outpatient nephrology clinic of interdisciplinary care. Methods: This is a prospective cohort study which was conducted over a year from October 2007, involving 149 patients invited to participate in the study at the time of their visit. Adherence to drug therapy was evaluated by a self-report method in an interview at baseline and 12 months later. We evaluated adherence to drug classes of antihypertensive beta-blockers (BB), angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARB), calcium channel blockers (CCB), diuretics, statins, and acetylsalicylic acid. The patient that reported the drugs and the respective number of prescribed pills in use in the visit that preceded the interview was considered adherent. Test Minimental State Examination (MMSE) was used to identify patients with cognitive decline, in which the assessment was done with their caregivers. Results: The univariate analysis performed at baseline showed that adherent patients (82.6%) differed from non-adherent (17.4%) due to their lower mean age (49 ± 16.8 vs 59 ± 14.1, p=0.006), use of fewer pills per day (6.3 ± 3.9 vs 8.5 ± 4.3, p=0.008), lower mean serum creatinine (1.84 ± 0.91 vs 2 32 ± 1.25, p=0.030), higher mean glomerular filtration rate (52.1 ± 29.31 vs 35.24 ± 19.03, p=0.01), absence of coronary artery disease (OR, 0.295; 95% CI, 0,096-0,902, p=0.037), such as more frequent comorbidity, and non reliance on caregivers for the administration of their medications (OR, 4.163, 95%, 1,688-10,269, p=0.003). After adjusting the logistic regression model, the factors that remained significantly associated with non-adherence were daily use of more than five pills (OR, 2.71, 95%, 0,99-7,41, p=0.052) and drug administration made by caregivers (OR, 3.53, 95%, 1,39-8,89, p=0.007). The longitudinal evaluation showed that the percentage of non-adherence increases with time, when comparing the baseline period with the final evaluation at 12 months (17% vs 27%, p=0.04). Conclusion: In the studied population, non-adherence was identified in 17.8% of the patients and significantly associated with the greatest number of pills used per day, drug administration by third parties, and with increase over the disease course.
386

Isolation and characterization of antiplasmodial metabolites from South African marine alga

Afolayan, Anthonia Folake January 2008 (has links)
Malaria is one of the three most deadly diseases in Africa. Although there are available treatments, their efficacy has been greatly reduced over the past two decades due to the development of resistance to currently available drugs. This has necessitated the search for new and effective antimalarial agents. This project approached the search for new antimalarial compounds in two ways: (i) by screening natural products isolated from marine algae against the Plasmodium parasite and (ii) by modification of selected isolated active compounds to target 1-deoxY-đ-xylulose 5-phosphate reductoisomerase (DXR), an enzyme found in the nonmevalonate isoprenoid biosynthetic pathway of Plasmodium Jalciparum. It was envisaged that such a compound would exhibit dual action on the Plasmodium parasite. Extracts obtained from 22 marine algae were prefractionated by solvent partitioning and were screened for anti plasmodial activity against the chloroquine sensitive (CQS) P. Jalciparum D 10 strain. Overall, 50% of the algae screened produced at least one crude fraction with activity against P. Jalciparum. Extracts of the algae Sargassum heterophyllum, Plocamium cornutum, Amphiroa ephedrea and Pterosiphonia cloiophylla gave the most promising results. Fractionation of S. heterophyllum afforded three tetraprenyltoluquinols (3.1, 3.2 and 3.5) and an all-trans-fucoxanthin (3.6). Three new compounds (4.5, 4.6 and 4.7) and two known halogenated monoterpenes (4.1 and 4.4) were isolated from P. cornutum. Each of the isolated compounds from both S. heterophyllum and P. cornutum showed antiplasmodial activity with IC₅₀ values ranging from 2.0 - 15.3 μM for S. heterophyllum and 13 - 230 μM for P. cornutum. Attempts to synthetically modify halogenated monoterpene 4.4 by dihydroxylation and phosphorylation in order to inhibit the DXR enzyme was unsuccessful. However, the hemiterpene analogue (5.42) of the halogenated monoterpenes was successfully phosphorylated and dihydroxylated to give compound 5.45 which showed promising activity against DXR. The result obtained indicated that the proposed phosphorylation and dihydroxylation of the halogenated monoterpene 4.4 would result in the synthesis of a potent DXR inhibitor and therefore a potential antimalarial agent with dual mode of action on the Plasmodium parasite.
387

Synthesis, Characterization And Anticancer Activity Of Copper(I) Phosphine Complexes

Sanghamitra, Nusrat Jahan Mobassarah 03 1900 (has links) (PDF)
No description available.
388

The chemoprophylaxis of meningococcal disease in the Cape Town City Council area : an evaluation of programme efficacy

Girdler-Brown, Brendan Vaughan January 1994 (has links)
This dissertation reports the findings of a study which was carried out in the Cape Town City Council area, in order to establish whether the offering of rifampicin to household contacts, of patients with meningococcal disease, resulted in protection of those contacts against developing the disease during a 32 week follow up period. The study took the form of a retrospective follow up of 3 350 household contacts of 412 cases notified over a 4-year period (mid 1988-mid 1992). It was found that the offering of rifampicin to the household contacts resulted in an odds ratio of not developing meningococcal disease over the 32-week follow up period of 14, 17 (SD = 12, 34). Although there was a tendency for contacts who were not offered rifampicin to have been younger, and of male gender, when compared to those who were offered prophylaxis, these demographic differences were not statistically significant at the 0,05 level. Furthermore, three out of the four male second cases, all in the younger age group, were in fact offered prophylaxis. It seems desirable that prophylaxis should be given as soon as possible. It is concluded, therefore, that the offering of rifampicin to household contacts of patients with meningococcal disease, living under the prevailing social circumstances in the Western Cape, has protective benefit for those contacts. It is likely that the chemoprophylaxis programme prevented up to 88 cases of meningococcal disease over the study period of four years, as well as preventing 8 deaths from this disease, in the CCC population.
389

Immune correlates of viral control in chronic HIV infection

Huang, Kenneth Hsing-Chung. January 2008 (has links)
No description available.
390

DARPP-32 expression in acquired resistance of breast cancer cells to trastuzumab

Hamel, Sophie. January 2007 (has links)
No description available.

Page generated in 0.0675 seconds